![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 10, 2020
This phase III trial is testing the antibody durvalumab added to standard chemoradiation followed by durvalumab for one year, compared to standard chemoradiation followed by one year of the antibody
June 10, 2020
This phase II study is exploring the potent FLT3 inhibitor gilteritinib
June 10, 2020
The study results, as well as correlative analyses, will be reported in an upcoming medical meeting
June 10, 2020
TMIST will provide data that is critical for relating the increased rate of detection of early breast cancers to the clinical outcomes of the screening population
June 10, 2020
The new virtual meeting format, developed out of necessity, sparked interesting conversations
May 29, 2020
What we know about COVID-19; remembering Valerie Guild; spotlight on Indiana University's Melvin and Bren Simon Comprehensive Cancer Center
May 29, 2020
May 29, 2020
The purpose of this trial is to better understand the coronavirus' effect on people with cancer
May 29, 2020
May 29, 2020
May 29, 2020
A Standing Main Member of ECOG-ACRIN since 1986
May 29, 2020
